Biotech RadarJobs updated

COMPANY

Brii Biosciences

briibio.com ↗

Clinical Phase 2

Profile checked Oct 10, 2026

Keywords: COVID-19 Chronic Hepatitis B Chronic Hepatitis B Virus Infection Chronic Hepatitis B Virus (HBV) Infection Severe Postpartum Depression For Treatment of Chronic Hepatitis B Virus Infection Postpartum Depression BRII-835 (VIR-2218) BRII-179 BRII-179 (VBI-2601) BRII-835 BRII-296 VIR-2218 BRII-297 BRII-198 BRII-196

12Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) source ↗
  2. Trial start Phase 2: Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) source ↗
  3. Trial start Phase 2: A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD) source ↗
  4. Trial start Phase 2: Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients source ↗
  5. Trial start Phase 1: A Study of BRII-297 in Healthy Adult Subjects source ↗
  6. Trial start Phase 2: A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 source ↗
  7. Trial start Phase 2: Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection source ↗
  8. Trial start Phase 2: A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 source ↗
  9. Trial start 1: A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 source ↗
  10. Trial start Phase 2: Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China source ↗
  11. Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198 source ↗
  12. Trial start Phase 1: Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196 source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 12

RecordTitlePhaseStatusStartPrimary completion
NCT04749368Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) InfectionPhase 2CompletedApr 12, 2021Jul 4, 2023 (actual)
NCT05970289Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV PatientsPhase 2Active, not recruitingAug 22, 2023Jul 16, 2025 (actual)
NCT06650852A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)Phase 2RecruitingOct 31, 20242026-07 (estimated)
NCT06057012A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD)Phase 2CompletedSep 29, 2023Mar 13, 2024 (actual)
NCT06491563Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)Phase 2Active, not recruitingAug 6, 20242026-12 (estimated)
NCT04507269Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland ChinaPhase 2CompletedAug 18, 2020Sep 30, 2021 (actual)
NCT05845840A Study of BRII-297 in Healthy Adult SubjectsPhase 1CompletedMay 15, 2023Nov 21, 2023 (actual)
NCT04691180A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-1981CompletedJan 5, 2021Sep 16, 2021 (actual)
NCT04479644Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-198Phase 1CompletedJul 13, 2020Feb 3, 2021 (actual)
NCT04479631Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196Phase 1CompletedJul 12, 2020Jan 29, 2021 (actual)
NCT04770467A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19Phase 2Withdrawn2021-022022-10 (estimated)
NCT04787211A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198Phase 2CompletedJun 20, 2021Dec 2, 2021 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback